They categorized SCLC into four types based on TME association with resistance to platinum-based therapy: SCLC-A with ASCL1 expression, SCLC-I with PD-L1 expression, SCLC-N with NEUROD1 expression, and SCLC-P with POU2F3 expression. Here, NEUROD1 is linked to small cell lung carcinoma.